Most undervalued stock, page-229

Here is an article talking about significant results for the reduction of viral shedding (yes I'm aware it is written by a potential competitor talking about GEN-003). I don't know enough about this stuff to argue the point but it made me question the companies expectations, and not for the first time. Make of it what you will.

https://liveherpesvaccine.com/2016/09/30/gen-003-yet-more-dragon-slaying-research/

In terms of HSV-2 virus shedding, a study would have to show a 5,000 to 10,000% reduction in HSV-2 shedding (50- to 100-fold) to achieve statistical significance at the p< 0.0001 level, and if GEN-003 vaccination elicited a 50- to 100-fold reduction in HSV-2 shedding, then they would not be leading with the “consolation prize argument” of achieving statistical significance at the p<0.05-level.
In practical terms, less than a 2.0-fold effect in science is generally a losing proposition, and a 1.0-fold effect is, by definition, “NO EFFECT” at all.  Real scientific discoveries that are worth talking about are generally based upon 5- to 500-fold effects.  The latest GEN-003 vaccine press-release reports that their therapeutic HSV-2 vaccine achieves a 1.7-fold reduction in HSV-2 shedding that is simply not worth discussing.